$SGRY
Surgery Partners, Inc. Stock $sgry

$sgry Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000163883315000007 Filed on November 13, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q3
Revenue	$263.3M	$239.6M	$76.30M
YoY Change	46.54%	214.01%
Cost Of Revenue	$183.2M	$168.8M	$45.38M
YoY Change	51.9%	272.04%
Gross Profit	$80.15M	$70.78M	$30.93M
YoY Change	35.61%	128.86%
Gross Profit Margin	30.44%	29.54%	40.53%
Selling, General & Admin	$40.20M	$28.30M	$11.80M
YoY Change	60.16%	139.83%
% of Gross Profit	50.16%	39.98%	38.16%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$9.000M	$8.611M	$2.834M
YoY Change	38.46%	203.85%
% of Gross Profit	11.23%	12.17%	9.16%
Operating Expenses	$49.10M	$195.3M	$56.65M
YoY Change	55.38%	244.8%
Operating Profit	$31.05M	$44.27M	$19.65M
YoY Change	12.89%	125.27%
Interest Expense	-$21.60M	-$26.57M	-$11.26M
YoY Change	-23.13%	135.93%
% of Operating Profit	-69.57%	-60.02%	-57.31%
Other Income/Expense, Net	-$117.9M	$300.0K	$0.00
YoY Change	-3567.65%
Pretax Income	-$121.3M	$17.70M	$8.391M
YoY Change	266.47%	110.95%
Income Tax	-$157.4M	$3.917M	$7.961M
% Of Pretax Income		22.13%	94.88%
Net Earnings	$16.74M	-$3.122M	-$6.908M
YoY Change	-130.85%	-54.81%
Net Earnings / Revenue	6.36%	-1.3%	-9.05%
Basic Earnings Per Share	$0.35	-$0.10	-$0.22
Diluted Earnings Per Share	$0.35	-$0.10	-$0.22
COMMON SHARES
Basic Shares Outstanding	48.16M shares	32.05M shares	31.70M shares
Diluted Shares Outstanding		32.05M shares	31.70M shares

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$57.90M	$56.80M
YoY Change	-22.7%
Cash & Equivalents	$57.93M	$56.85M	$4.386M
Short-Term Investments
Other Short-Term Assets	$8.414M	$9.662M
YoY Change	-10.48%
Inventory	$25.59M	$24.75M
Prepaid Expenses	$7.409M	$8.122M
Receivables	$177.8M	$164.6M
Other Receivables	$19.80M	$10.00M
Total Short-Term Assets	$311.0M	$288.0M
YoY Change	15.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$184.6M	$173.8M
YoY Change	5.49%
Goodwill	$1.408B	$1.330B
YoY Change	8.41%
Intangibles	$53.57M	$53.14M
YoY Change	-2.4%
Long-Term Investments	$36.90M	$36.60M
YoY Change	2.5%
Other Assets	$10.51M	$7.510M
YoY Change	78.75%
Total Long-Term Assets	$1.793B	$1.604B
YoY Change	12.79%
TOTAL ASSETS
Total Short-Term Assets	$311.0M	$288.0M
Total Long-Term Assets	$1.793B	$1.604B
Total Assets	$2.104B	$1.892B
YoY Change	13.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$45.34M	$40.81M
YoY Change	5.29%
Accrued Expenses	$53.90M	$51.10M
YoY Change	16.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$27.20M	$27.70M
YoY Change	23.08%
Total Short-Term Liabilities	$181.3M	$176.2M
YoY Change	28.22%
LONG-TERM LIABILITIES
Long-Term Debt	$1.282B	$1.425B
YoY Change	-7.77%
Other Long-Term Liabilities	$85.61M	$83.78M
YoY Change	-5.51%
Total Long-Term Liabilities	$85.61M	$83.78M
YoY Change	-5.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$181.3M	$176.2M
Total Long-Term Liabilities	$85.61M	$83.78M
Total Liabilities	$266.9M	$260.0M
YoY Change	15.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$320.8M	-$337.5M
YoY Change	-0.44%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.028M	-$277.4M
YoY Change
Total Liabilities & Shareholders Equity	$2.104B	$1.892B
YoY Change	13.22%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	$16.74M	-$3.122M	-$6.908M
YoY Change	-130.85%	-54.81%
Depreciation, Depletion And Amortization	$9.000M	$8.611M	$2.834M
YoY Change	38.46%	203.85%
Cash From Operating Activities	$24.20M	$29.30M	$14.30M
YoY Change	-431.51%	104.9%
INVESTING ACTIVITIES
Capital Expenditures	-$15.30M	-$6.600M	-$1.200M
YoY Change	155.0%	450.0%
Acquisitions
YoY Change
Other Investing Activities	-$80.00M	-$20.20M	-$600.0K
YoY Change	-69.34%	3266.67%
Cash From Investing Activities	-$95.30M	-$26.80M	-$1.800M
YoY Change	-64.29%	1388.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	72.30M	6.400M	-14.10M
YoY Change	-79.03%	-145.39%
NET CHANGE
Cash From Operating Activities	24.20M	29.30M	14.30M
Cash From Investing Activities	-95.30M	-26.80M	-1.800M
Cash From Financing Activities	72.30M	6.400M	-14.10M
Net Change In Cash	1.200M	8.900M	-1.600M
YoY Change	-98.3%	-656.25%
FREE CASH FLOW
Cash From Operating Activities	$24.20M	$29.30M	$14.30M
Capital Expenditures	-$15.30M	-$6.600M	-$1.200M
Free Cash Flow	$39.50M	$35.90M	$15.50M
YoY Change	-3138.46%	131.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001638833
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48156990	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Surgery Partners, Inc.
	smbi	Amortizationof Unfavorable Lease Liability AmortizationofUnfavorableLeaseLiability	0	USD
	smbi	Amortizationof Unfavorable Lease Liability AmortizationofUnfavorableLeaseLiability	-323000	USD
	smbi	Business Acquisition Numberof Physicians Addedto Network BusinessAcquisitionNumberofPhysiciansAddedtoNetwork	14	Physician
CY2014Q4	smbi	Business Combination Consideration Transferred Payable Current BusinessCombinationConsiderationTransferredPayableCurrent	0	USD
CY2015Q3	smbi	Business Combination Consideration Transferred Payable Current BusinessCombinationConsiderationTransferredPayableCurrent	16768000	USD
CY2014Q4	smbi	Business Combination Consideration Transferred Payable Noncurrent BusinessCombinationConsiderationTransferredPayableNoncurrent	16768000	USD
CY2015Q3	smbi	Business Combination Consideration Transferred Payable Noncurrent BusinessCombinationConsiderationTransferredPayableNoncurrent	0	USD
CY2014Q4	smbi	Business Combination Indemnification Assets Receivable BusinessCombinationIndemnificationAssetsReceivable	1072000	USD
CY2015Q3	smbi	Business Combination Indemnification Assets Receivable BusinessCombinationIndemnificationAssetsReceivable	1072000	USD
CY2014Q4	smbi	Escrow Deposit Current EscrowDepositCurrent	0	USD
CY2015Q3	smbi	Escrow Deposit Current EscrowDepositCurrent	14054000	USD
CY2014Q4	smbi	Escrow Deposit Noncurrent EscrowDepositNoncurrent	16232000	USD
CY2015Q3	smbi	Escrow Deposit Noncurrent EscrowDepositNoncurrent	0	USD
CY2014Q4	smbi	Escrow Liability Current EscrowLiabilityCurrent	0	USD
CY2015Q3	smbi	Escrow Liability Current EscrowLiabilityCurrent	14054000	USD
CY2014Q4	smbi	Escrow Liability Noncurrent EscrowLiabilityNoncurrent	16232000	USD
CY2015Q3	smbi	Escrow Liability Noncurrent EscrowLiabilityNoncurrent	0	USD
CY2013Q2	smbi	Gain Contingency Unrecorded Amount Overstated Accounts Receivable GainContingencyUnrecordedAmountOverstatedAccountsReceivable	10800000	USD
CY2014Q3	smbi	Incentive Payments Recognizedfor Certain Hospitalsand Physician Practices That Demonstrate Meaningful Useof Certified Electronic Health Record Technology IncentivePaymentsRecognizedforCertainHospitalsandPhysicianPracticesThatDemonstrateMeaningfulUseofCertifiedElectronicHealthRecordTechnology	0	USD
	smbi	Incentive Payments Recognizedfor Certain Hospitalsand Physician Practices That Demonstrate Meaningful Useof Certified Electronic Health Record Technology IncentivePaymentsRecognizedforCertainHospitalsandPhysicianPracticesThatDemonstrateMeaningfulUseofCertifiedElectronicHealthRecordTechnology	0	USD
CY2015Q3	smbi	Incentive Payments Recognizedfor Certain Hospitalsand Physician Practices That Demonstrate Meaningful Useof Certified Electronic Health Record Technology IncentivePaymentsRecognizedforCertainHospitalsandPhysicianPracticesThatDemonstrateMeaningfulUseofCertifiedElectronicHealthRecordTechnology	57000	USD
	smbi	Incentive Payments Recognizedfor Certain Hospitalsand Physician Practices That Demonstrate Meaningful Useof Certified Electronic Health Record Technology IncentivePaymentsRecognizedforCertainHospitalsandPhysicianPracticesThatDemonstrateMeaningfulUseofCertifiedElectronicHealthRecordTechnology	107000	USD
CY2015Q3	smbi	Increaseof Revenueas Resultof Changesin Estimatesto Thirdparty Settlements Relatedto Prior Years IncreaseofRevenueasResultofChangesinEstimatestoThirdpartySettlementsRelatedtoPriorYears	1800000	USD
	smbi	Increaseof Revenueas Resultof Changesin Estimatesto Thirdparty Settlements Relatedto Prior Years IncreaseofRevenueasResultofChangesinEstimatestoThirdpartySettlementsRelatedtoPriorYears	1500000	USD
	smbi	Intangible Assets Professional Recruitment Expense IntangibleAssetsProfessionalRecruitmentExpense	500000	USD
CY2014Q4	smbi	Lease Obligation Noncurrent LeaseObligationNoncurrent	50749000	USD
CY2015Q3	smbi	Lease Obligation Noncurrent LeaseObligationNoncurrent	54220000	USD
CY2014Q4	smbi	Medical Malpractice Liability Noncurrent MedicalMalpracticeLiabilityNoncurrent	4253000	USD
CY2015Q3	smbi	Medical Malpractice Liability Noncurrent MedicalMalpracticeLiabilityNoncurrent	4253000	USD
	smbi	Non Controlling Interest Acquisitionsand Disposalsof Interestsheldby Non Controlling Interest Holders Net NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersNet	-2208000	USD
CY2015Q3	smbi	Number Of Surgical Facilities Owned NumberOfSurgicalFacilitiesOwned	99	surgical_facility
CY2015Q3	smbi	Numberof Surgical Facilities Owned Consolidated NumberofSurgicalFacilitiesOwnedConsolidated	88	surgical_facility
CY2015Q3	smbi	Numberof Surgical Facilities Owned Majority Interest NumberofSurgicalFacilitiesOwnedMajorityInterest	71	surgical_facility
	smbi	Numberof Surgical Facilities Relatedto Revenue Adjustment NumberofSurgicalFacilitiesRelatedtoRevenueAdjustment	2	surgical_facility
CY2015Q3	smbi	Operating Leasesof Lessee Accrued Liabilityrelatedto Leases Terminated OperatingLeasesofLesseeAccruedLiabilityrelatedtoLeasesTerminated	4600000	USD
CY2015Q3	smbi	Operating Leasesof Lessee Numberof Leases Terminated OperatingLeasesofLesseeNumberofLeasesTerminated	4	Lease
CY2014Q4	smbi	Optical Products Receivable OpticalProductsReceivable	7556000	USD
CY2015Q3	smbi	Optical Products Receivable OpticalProductsReceivable	8894000	USD
	smbi	Paymentsof Distributionto Parent PaymentsofDistributiontoParent	93000000	USD
	smbi	Paymentsof Distributionto Parent PaymentsofDistributiontoParent	0	USD
	smbi	Redeemable Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	15471000	USD
	smbi	Redeemable Noncontrolling Interest Increase Decrease From Redemptions Or Purchase Of Interests RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests	-6264000	USD
CY2014Q4	smbi	Third Party Settlements Payable Current ThirdPartySettlementsPayableCurrent	11708000	USD
CY2015Q3	smbi	Third Party Settlements Payable Current ThirdPartySettlementsPayableCurrent	6921000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	43063000	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	40807000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	144960000	USD
CY2015Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	164604000	USD
CY2014Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	5552000	USD
CY2015Q3	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	4897000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	55697000	USD
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	65810000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	58151000	USD
CY2015Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	59766000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1279000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	5329000	USD
CY2015Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	12693000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2395000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4966000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6672000	USD
CY2014Q4	us-gaap	Assets Assets	1858794000	USD
CY2015Q3	us-gaap	Assets Assets	1891522000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	268649000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	288003000	USD
CY2013Q2	us-gaap	Business Combination Assets Arising From Contingencies Amount Recognized BusinessCombinationAssetsArisingFromContingenciesAmountRecognized	14000000	USD
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	13009000	USD
CY2015Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	13789000	USD
CY2014Q3	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	325000	USD
	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	442000	USD
CY2015Q3	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	1249000	USD
	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	14897000	USD
CY2014Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	10755000	USD
CY2015Q3	us-gaap	Capital Lease Obligations CapitalLeaseObligations	10342000	USD
CY2014Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	13300000	USD
CY2015Q3	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	11300000	USD
CY2014Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	6800000	USD
CY2015Q3	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	9700000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13026000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4386000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74920000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56848000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8640000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-18072000	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1000	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33871990	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1000	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33871990	shares
CY2014Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	USD
CY2015Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	339000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6908000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11633000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3122000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15310000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	7338000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	21346000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	16906000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	52061000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	430000	USD
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22370000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	9713000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	13784000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	36751000	USD
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	45377000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	133591000	USD
CY2015Q3	us-gaap	Cost Of Revenue CostOfRevenue	168821000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	486152000	USD
CY2014Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	1415000	USD
CY2015Q3	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	1522000	USD
CY2014Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	1402000	USD
CY2015Q3	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	1522000	USD
CY2014Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	5630000	USD
CY2015Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	4816000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	10742000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	7419000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	49170000	USD
CY2015Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	59749000	USD
CY2014Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2834000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8557000	USD
CY2015Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8611000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25538000	USD
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2015Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23391000	USD
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	5421000	USD
CY2014Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	8000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-110000	USD
CY2015Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1161000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1522000	USD
CY2014Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1975000	USD
CY2015Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6738000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20038000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11236000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34944000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	1298753000	USD
CY2015Q3	us-gaap	Goodwill Goodwill	1330050000	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	40649000	USD
	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-953000	USD
	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	8399000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12043000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3917000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8368000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9442000	USD
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	7027000	USD
CY2015Q3	us-gaap	Interest Payable Current InterestPayableCurrent	6744000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	23692000	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	8391000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	21756000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	17701000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	45119000	USD
CY2015Q3	us-gaap	Inventory Net InventoryNet	24747000	USD
CY2014Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	33441000	USD
CY2015Q3	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	33877000	USD
CY2014Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	18743000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	55390000	USD
CY2015Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	66072000	USD
CY2014Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2015Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1320000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2866000	USD
	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	0	USD
	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	316000	USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7961000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	34538000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-431000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-4989000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	54888000	USD
CY2015Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53137000	USD
CY2014Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-11263000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-32718000	USD
CY2015Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-26573000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-78507000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	188405000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1858794000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1891522000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	141391000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	176177000	USD
CY2014Q4	us-gaap	Long Term Accounts Notes And Loans Receivable Net Noncurrent LongTermAccountsNotesAndLoansReceivableNetNoncurrent	182000	USD
CY2015Q3	us-gaap	Long Term Accounts Notes And Loans Receivable Net Noncurrent LongTermAccountsNotesAndLoansReceivableNetNoncurrent	222000	USD
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1339266000	USD
CY2015Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1370991000	USD
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	22088000	USD
CY2015Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	27678000	USD
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	1361354000	USD
CY2015Q3	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	1398669000	USD
CY2014Q4	us-gaap	Minority Interest MinorityInterest	293618000	USD
CY2015Q3	us-gaap	Minority Interest MinorityInterest	294684000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	35724000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-33778000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-38880000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4096000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-39484000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	29234000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	60292000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-6908000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11633000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-3122000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15310000	USD
CY2014Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	7338000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	21346000	USD
CY2015Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	16906000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	52061000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	12727000	USD
	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	24024000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2015Q3	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	28	state
CY2014Q4	us-gaap	Off Market Lease Unfavorable OffMarketLeaseUnfavorable	2427000	USD
CY2015Q3	us-gaap	Off Market Lease Unfavorable OffMarketLeaseUnfavorable	2104000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	56649000	USD
	us-gaap	Operating Expenses OperatingExpenses	169124000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	195325000	USD
	us-gaap	Operating Expenses OperatingExpenses	572943000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	19654000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	54474000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	44274000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	123626000	USD
CY2014Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3651000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	10841000	USD
CY2015Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	11211000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	33267000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	16918000	USD
CY2015Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20977000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	9399000	USD
CY2015Q3	us-gaap	Other Assets Current OtherAssetsCurrent	9662000	USD
CY2014Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	2099000	USD
CY2015Q3	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	3361000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5879000	USD
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7510000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2014Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	3534000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	10522000	USD
CY2015Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	13928000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	39786000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	53870000	USD
CY2015Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	70247000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	90610000	USD
CY2015Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	83778000	USD
CY2014Q3	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	0	USD
	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	0	USD
CY2015Q3	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	-330000	USD
	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	-356000	USD
CY2014Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	1989000	USD
CY2015Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8122000	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2015Q3	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	7890000	USD
CY2014Q4	us-gaap	Payables To Customers PayablesToCustomers	9476000	USD
CY2015Q3	us-gaap	Payables To Customers PayablesToCustomers	10570000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	86000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2120000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	275000	USD
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	11991000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	21408000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	51195000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1448000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	659000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	32562000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3437000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18115000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	24005000	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	26678000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7050000	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11193000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	146651000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	85432000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	3783000	USD
CY2014Q3	us-gaap	Professional Fees ProfessionalFees	2320000	USD
	us-gaap	Professional Fees ProfessionalFees	6770000	USD
CY2015Q3	us-gaap	Professional Fees ProfessionalFees	17233000	USD
	us-gaap	Professional Fees ProfessionalFees	48144000	USD
CY2014Q3	us-gaap	Profit Loss ProfitLoss	430000	USD
	us-gaap	Profit Loss ProfitLoss	9713000	USD
CY2015Q3	us-gaap	Profit Loss ProfitLoss	13784000	USD
	us-gaap	Profit Loss ProfitLoss	36751000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross Excluding Capital Leased Assets PropertyPlantAndEquipmentGrossExcludingCapitalLeasedAssets	230703000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Gross Excluding Capital Leased Assets PropertyPlantAndEquipmentGrossExcludingCapitalLeasedAssets	239623000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net Excluding Capital Leased Assets PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets	175006000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net Excluding Capital Leased Assets PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets	173813000	USD
CY2014Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1383000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4411000	USD
CY2015Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5840000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	16049000	USD
CY2014Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	192589000	USD
CY2015Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	183581000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	63540000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	63461000	USD
CY2014Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	316000	USD
CY2015Q3	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	316000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-322233000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-337543000	USD
CY2014Q3	us-gaap	Revenues Revenues	76303000	USD
	us-gaap	Revenues Revenues	223598000	USD
CY2015Q3	us-gaap	Revenues Revenues	239599000	USD
	us-gaap	Revenues Revenues	696569000	USD
CY2014Q4	us-gaap	Security Deposit SecurityDeposit	2196000	USD
CY2015Q3	us-gaap	Security Deposit SecurityDeposit	2405000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	342000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1279000	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	339000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-264082000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	-277438000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29536000	USD
CY2015Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17246000	USD
CY2014Q3	us-gaap	Supplies Expense SuppliesExpense	17129000	USD
	us-gaap	Supplies Expense SuppliesExpense	50068000	USD
CY2015Q3	us-gaap	Supplies Expense SuppliesExpense	60377000	USD
	us-gaap	Supplies Expense SuppliesExpense	176550000	USD
CY2014Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	3189000	USD
CY2015Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	3370000	USD
CY2014Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2015Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31698638	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31698638	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32054089	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32054089	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31698638	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31698638	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32054089	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32054089	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">Surgery Partners, Inc.</font><font style="font-family:inherit;font-size:9pt;">,</font><font style="font-family:inherit;font-size:10pt;"> a </font><font style="font-family:inherit;font-size:9pt;">Delaware corporation (together with its subsidiaries, the “Company”), was formed April 2, 2015, as a holding company for the purpose of facilitating an initial public offering (the “IPO”) of shares of common stock. Prior to September 30, 2015, the Company conducted business through Surgery Center Holdings, Inc. and its subsidiaries. Surgery Center Holdings, LLC was and is the sole direct owner of the equity interests of Surgery Center Holdings, Inc. and had no other material assets. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">On September 30, 2015, Surgery Partners, Inc. became the direct parent and sole member of Surgery Center Holdings, LLC (the "Reorganization"). In the Reorganization, all of the equity interests held by the existing owners of Surgery Center Holdings, LLC were contributed to Surgery Partners, Inc. in exchange for </font><font style="font-family:inherit;font-size:9pt;">33,871,990</font><font style="font-family:inherit;font-size:9pt;"> shares of common stock of Surgery Partners, Inc. and certain rights to additional payments under a tax receivable agreement. After giving effect to the Reorganization, Surgery Partners, Inc. is a holding company, and its sole material asset is an equity interest in Surgery Center Holdings, LLC. The Company's condensed consolidated financial statements for periods prior to the Reorganization represent the historical operating results and financial position of Surgery Center Holdings, Inc. and certain of its subsidiaries.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">On </font><font style="font-family:inherit;font-size:9pt;">November 3, 2014</font><font style="font-family:inherit;font-size:9pt;">, the Company completed the acquisition of Symbion Holdings Corp. ("Symbion") ("the Merger"), which added </font><font style="font-family:inherit;font-size:9pt;">55</font><font style="font-family:inherit;font-size:9pt;"> surgical facilities, including </font><font style="font-family:inherit;font-size:9pt;">49</font><font style="font-family:inherit;font-size:9pt;"> ambulatory surgery centers ("ASCs") and </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:9pt;"> surgical hospitals, to its network of existing facilities. The Company acquired Symbion for a purchase price of </font><font style="font-family:inherit;font-size:9pt;">$792.0 million</font><font style="font-family:inherit;font-size:9pt;"> pursuant to the terms of an Agreement and Plan of Merger dated as of </font><font style="font-family:inherit;font-size:9pt;">June 13, 2014</font><font style="font-family:inherit;font-size:9pt;">. The Symbion acquisition was financed through the issuance of approximately </font><font style="font-family:inherit;font-size:9pt;">$1.4 billion</font><font style="font-family:inherit;font-size:9pt;"> under the Company's Term Loans and Revolving Facility. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As of </font><font style="font-family:inherit;font-size:9pt;">September 30, 2015</font><font style="font-family:inherit;font-size:9pt;">, the Company owned and operated a national network of surgical facilities and ancillary services in </font><font style="font-family:inherit;font-size:9pt;">28</font><font style="font-family:inherit;font-size:9pt;"> states.  The surgical facilities, which include ASCs and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, cardiology, gastroenterology, ophthalmology, orthopedics and pain management. Some of the Company's surgical hospitals also provide acute care services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of a diagnostic laboratory, multi-specialty physician practices, urgent care facilities, anesthesia services, optical services and specialty pharmacy services. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> As of </font><font style="font-family:inherit;font-size:9pt;">September 30, 2015</font><font style="font-family:inherit;font-size:9pt;">, the Company owned or operated a portfolio of </font><font style="font-family:inherit;font-size:9pt;">99</font><font style="font-family:inherit;font-size:9pt;"> surgical facilities, comprised of </font><font style="font-family:inherit;font-size:9pt;">94</font><font style="font-family:inherit;font-size:9pt;"> ASCs, of which </font><font style="font-family:inherit;font-size:9pt;">six</font><font style="font-family:inherit;font-size:9pt;"> are managed only, and </font><font style="font-family:inherit;font-size:9pt;">five</font><font style="font-family:inherit;font-size:9pt;"> surgical hospitals. The Company owns these facilities in partnership with physicians and, in some cases, healthcare systems in the markets and communities it serves. The Company owned a majority interest in </font><font style="font-family:inherit;font-size:9pt;">71</font><font style="font-family:inherit;font-size:9pt;"> of the surgical facilities and consolidated </font><font style="font-family:inherit;font-size:9pt;">88</font><font style="font-family:inherit;font-size:9pt;"> of these facilities for financial reporting purposes. In addition, the Company operated or managed a network of </font><font style="font-family:inherit;font-size:9pt;">43</font><font style="font-family:inherit;font-size:9pt;"> physician practices.</font></div></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certain reclassifications have been made to the comparative periods' financial statements to conform to the three and </font><font style="font-family:inherit;font-size:9pt;">nine months ended</font><font style="font-family:inherit;font-size:9pt;"> </font><font style="font-family:inherit;font-size:9pt;">September 30, 2015</font><font style="font-family:inherit;font-size:9pt;"> presentation. The reclassifications primarily related to the presentation of certain expenses within costs of revenue and had no impact on the Company's consolidated financial position, results of operations or cash flows.</font></div></div>
	us-gaap	Revenue Recognition Sales Of Services RevenueRecognitionSalesOfServices	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">Other service revenues.</font><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:inherit;font-size:9pt;"> Optical service revenues consist of product sales from the Company's optical laboratories as well as handling charges billed to the members of the Company's optical products purchasing organization and sales from the Company's marketing products and services business. The Company's optical products purchasing organization negotiates volume buying discounts with optical products manufacturers. The buying discounts and any handling charges billed to the members of the buying group represent the revenue recognized for financial reporting purposes. Revenue is recognized as orders are shipped to members. The Company bases its estimates for sales returns and discounts on historical experience and has not experienced significant fluctuations between estimated and actual return activity and discounts given. The Company's optical laboratories manufacture and distribute corrective lenses and eyeglasses to ophthalmologists and optometrists. Revenue is recognized when product is shipped, net of allowance for discounts. The Company's marketing products and services businesses recognize revenue when product is shipped or services are rendered. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which services are rendered.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The Company recognizes revenues in the period in which the services are performed. Patient service revenues and receivables from third-party payors are recorded net of estimated contractual adjustments and allowances, which the Company estimates based on the historical trend of its cash collections and contractual write-offs, accounts receivable agings, established fee schedules, contracts with payors and procedure statistics.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">Patient service revenues.</font><font style="font-family:inherit;font-size:9pt;">  The fee charged for healthcare procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications.  The fee does not normally include professional fees charged by the patient’s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor.  However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians. Patient service revenues are recognized on the date of service, net of estimated contractual adjustments and discounts from third-party payors, including Medicare and Medicaid.  Changes in estimated contractual adjustments and discounts are recorded in the period of change.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All adjustments are of a normal, recurring nature. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001638833-15-000007-index-headers.html	Edgar Link	pending
0001638833-15-000007-index.html	Edgar Link	pending
0001638833-15-000007.txt	Edgar Link	pending
0001638833-15-000007-xbrl.zip	Edgar Link	pending
exhibit101taxreceivableagr.htm	Edgar Link	pending
exhibit102registrationrigh.htm	Edgar Link	pending
exhibit103reorganizationag.htm	Edgar Link	pending
exhibit105formofoptionaward.htm	Edgar Link	pending
exhibit106formofdirectorop.htm	Edgar Link	pending
exhibit107formofrestricted.htm	Edgar Link	pending
exhibit108cashincentiveplan.htm	Edgar Link	pending
exhibit31amendedandrestate.htm	Edgar Link	pending
exhibit32amendedandrestate.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
q3201510-qfiling.htm	Edgar Link	pending
q32015exhibit311.htm	Edgar Link	pending
q32015exhibit312.htm	Edgar Link	pending
q32015exhibit321.htm	Edgar Link	pending
q32015exhibit322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
smbi-20150930.xml	Edgar Link	completed
smbi-20150930.xsd	Edgar Link	pending
smbi-20150930_cal.xml	Edgar Link	unprocessable
smbi-20150930_def.xml	Edgar Link	unprocessable
smbi-20150930_lab.xml	Edgar Link	unprocessable
smbi-20150930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SGRY
Surgery Partners, Inc. Stock $sgry

2015 Q4 Form 10-Q Financial Statement

#000163883315000007 Filed on November 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SGRY Surgery Partners, Inc. Stock $sgry

2015 Q4 Form 10-Q Financial Statement

#000163883315000007 Filed on November 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SGRY
Surgery Partners, Inc. Stock $sgry